Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
ONCYOncolytics Biotech (ONCY) Prnewswire·2024-09-19 19:00

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer Oncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorepbased therapy in advanced or metastatic breast cancer Over half of BRACELET-1 patients in the pelareorep + chemotherapy ...